{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:35:21Z","timestamp":1786736121474,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/jcrt.jcrt_577_18","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T05:44:58Z","timestamp":1578635098000},"page":"1435","source":"Crossref","is-referenced-by-count":12,"title":["Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: A meta-analysis"],"prefix":"10.4103","volume":"15","author":[{"given":"Xiaolong","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.275560-1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"key-10.4103\/0973-1482.275560-2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"key-10.4103\/0973-1482.275560-3","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4103\/0973-1482.187298","article-title":"Signal transducer and activator of transcription 3 downregulation in J774A.1 cell line as a model of M2 macrophages in tumor microenvironment","author":"Seyedi","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"key-10.4103\/0973-1482.275560-4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management","author":"Kroschinsky","year":"2017","journal-title":"Crit Care"},{"key":"key-10.4103\/0973-1482.275560-5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00259-017-3695-3","article-title":"Molecularly targeted therapies in cancer: A guide for the nuclear medicine physician","author":"Lheureux","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"key-10.4103\/0973-1482.275560-6","first-page":"S74","article-title":"Monoclonal antibodies in hematological malignancies: Past, present and future","author":"Tazi","year":"2013","journal-title":"J Cancer Res Ther"},{"key":"key-10.4103\/0973-1482.275560-7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/CMAR.S114526","article-title":"The clinical development of obinutuzumab for the treatment of follicular lymphoma","author":"Ma","year":"2017","journal-title":"Cancer Manag Res"},{"key":"key-10.4103\/0973-1482.275560-8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/DDDT.S119036","article-title":"Immunotherapy for the treatment of colorectal tumors: Focus on approved and in-clinical-trial monoclonal antibodies","author":"Fran\u00e7oso","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"key-10.4103\/0973-1482.275560-9","first-page":"4105615","article-title":"Current molecular targeted therapy in advanced gastric cancer: A Comprehensive review of therapeutic mechanism, clinical trials, and practical application","author":"Li","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"key-10.4103\/0973-1482.275560-10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejca.2017.01.026","article-title":"The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials","author":"Roviello","year":"2017","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0973-1482.275560-11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","article-title":"Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis","author":"Campiotti","year":"2017","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0973-1482.275560-12","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","article-title":"Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the acute leukemia working party of the European Society for Blood and Marrow Transplantation","author":"Giebel","year":"2016","journal-title":"Cancer"},{"key":"key-10.4103\/0973-1482.275560-13","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: A CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","author":"Goebeler","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"key-10.4103\/0973-1482.275560-14","first-page":"1","article-title":"Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma","author":"Mackiewicz","year":"2017","journal-title":"Contemp Oncol (Pozn)"},{"key":"key-10.4103\/0973-1482.275560-15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/1060028015586218","article-title":"Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology","author":"Barbee","year":"2015","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/0973-1482.275560-16","unstructured":"Reporting Serious Problems to FDA. What is a Serious Adverse Event? Vol. 2017; 2017. Available from: https:\/\/www.fda.gov\/safety\/medwatch\/howtoreport\/ucm053087.htm. [Last accessed on 2018 Feb 25]."},{"key":"key-10.4103\/0973-1482.275560-17","first-page":"1","article-title":"Deaths: Final data for 2006","author":"Heron","year":"2009","journal-title":"Natl Vital Stat Rep"},{"key":"key-10.4103\/0973-1482.275560-18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/annonc\/mdw549","article-title":"Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: A meta-analysis of phase 3 randomized controlled trials\u2020","author":"Gyawali","year":"2017","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0973-1482.275560-19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.275560-20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.eururo.2011.12.057","article-title":"Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: An exploratory analysis of the outcomes of elderly patients in the RECORD-1 trial","author":"Porta","year":"2012","journal-title":"Eur Urol"},{"key":"key-10.4103\/0973-1482.275560-21","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1586\/14737140.2014.953936","article-title":"Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis","author":"Abdel-Rahman","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"key-10.4103\/0973-1482.275560-22","first-page":"1711","article-title":"Risk of metabolic complications in patients with solid tumors treated with mTOR inhibitors: Meta-analysis","author":"Lew","year":"2016","journal-title":"Anticancer Res"},{"key":"key-10.4103\/0973-1482.275560-23","doi-asserted-by":"crossref","first-page":"e65166","DOI":"10.1371\/journal.pone.0065166","article-title":"Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: A meta-analysis","author":"Qi","year":"2013","journal-title":"PLoS One"},{"key":"key-10.4103\/0973-1482.275560-24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14740338.2017.1297420","article-title":"Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab","author":"Zhu","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"key-10.4103\/0973-1482.275560-25","doi-asserted-by":"crossref","first-page":"e1719","DOI":"10.1097\/MD.0000000000001719","article-title":"The risk of neutropenia and leukopenia in advanced non-small cell lung cancer patients treated with erlotinib: A prisma-compliant systematic review and meta-analysis","author":"Zhou","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"key-10.4103\/0973-1482.275560-26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2015.01.026","article-title":"Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer","author":"Takeda","year":"2015","journal-title":"Lung Cancer"},{"key":"key-10.4103\/0973-1482.275560-27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","article-title":"Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review","author":"Kroeze","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"key-10.4103\/0973-1482.275560-28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12885-015-1373-z","article-title":"Impact of neo-adjuvant sorafenib treatment on liver transplantation in HCC patients \u2013 A prospective, randomized, double-blind, phase III trial","author":"Hoffmann","year":"2015","journal-title":"BMC Cancer"},{"key":"key-10.4103\/0973-1482.275560-29","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275560-30","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(13)70479-0","article-title":"Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial","author":"Araujo","year":"2013","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0973-1482.275560-31","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","article-title":"Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer","author":"Baselga","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275560-32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"key":"key-10.4103\/0973-1482.275560-33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2011.37.1195","article-title":"Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors","author":"Schutz","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275560-34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial","author":"Motzer","year":"2008","journal-title":"Lancet"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:37:34Z","timestamp":1786732654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_577_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"alternative-id":["275560"],"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_577_18","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}